Hematology/Oncology

Top Story

Molecular prognostic index may predict survival in early-stage NSCLC

September 1, 2015

A nine-gene molecular prognostic index provided accurate risk stratification and may be used to inform adjuvant therapy for patients with early-stage non–small cell lung cancer, according to the results of a retrospective analysis.

“We set out to develop a predictor that could identify which patients with early-stage NSCLC are at highest risk for dying of the disease,” Maximilian Diehn, MD, PhD, assistant professor of radiation oncology at Stanford University School of Medicine, told HemOnc Today. “Such a predictor could potentially help identify patients who would be most likely to benefit from adjuvant therapy after definitive local treatment. We also wanted our predictor to incorporate both gene expression and clinical risk factors in order to take advantage of both types of information.”

Julie M. Vose, MD, MBA, FASCO In the Journals

Rapid growth of genetic genomic testing leads to ASCO policy statement update

August 31, 2015
ASCO updated its policy statement on genetic and genomic testing for cancer susceptibility.The statement highlights the way new technologies have changed the assessment…

Regen developing new gene procedure for targeting liver cancer cells

August 31, 2015
Regen BioPharma, Inc. announced it is currently developing a gene delivery procedure that will enable RGBP-248, a gene silencing nucleic acid, to reach liver tumors and…
Gregory Masters In the Journals

ASCO updates guideline on treatment of advanced NSCLC

August 31, 2015
ASCO has updated its clinical practice guideline on systemic therapy for stage IV non–small cell lung cancer.The evidence-based recommendations provide guidance on…

Patients with RA may be at greater risk for developing lung cancer, lymphoma

August 31, 2015
Patients with rheumatoid arthritis may have a higher risk for developing lung cancer or lymphoma compared with the general population but may be at lower risk for…
More News Headlines »
CME
Updates in Immunotherapy – Philadelphia 2015

Updates in Immunotherapy – Philadelphia 2015

This activity is supported by an educational grant from Merck & Co., Inc.

The promise of immunotherapy in oncology has become a reality with the US Food and Drug Administration (FDA) approval…
More »
Meeting News Coverage Video
VIDEO: PALOMA-3 trial represents 'enormous gain' for patients with hormone-positive breast cancer

VIDEO: PALOMA-3 trial represents 'enormous gain' for patients with hormone-positive breast cancer

August 20, 2015
CHICAGO — The PALOMA-3 trial, which evaluated the addition of palbociclib to fulvestrant, demonstrated…
More »
CME
Hematology Oncology Case Consults

The Patient with Multiple Myeloma

No commercial support for this activity.

This CME activity will focus on the diagnosis and management of patients with multiple myeloma.
More »
morganatic-roan